The effect of Memantine on the severity of symptoms and brain function in patients with Obsessive-Compulsive Disorder (OCD) : An Event Related Potential (ERP) study
- Conditions
- obsessive-compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT20130518013359N5
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Patients with obsessive-compulsive disorder who have been treated with high doses of SSRI for at least 8 weeks but whose Y-BOCS index is higher than cut-off 15.
People aged 18 to 60 years
Obtain patient informed consent
Pregnancy or breastfeeding
Using serotonergic drugs other than SSRIs
Use of NMDA receptor antagonists other than memantine
Psychotic and bipolar disorders (based on DSM-5 criteria)
Major Depressive Disorder (Based on DSM-IV-TR Criteria)
Other anxiety disorders (such as panic disorder, post-traumatic stress disorder (PTSD), general anxiety disorder (GAD)
Abuse or dependence on drugs or alcohol
Liver dysfunction (LFT> 3ULN)
Kidney dysfunction (GFR <60 ml / kg / min)
Thyroid Disorders (Based on Thyroid Function Test)
History of seizures
Cognitive-behavioral therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the effect of memantine in comparison with placebo on reducing the severity of symptoms in patients with obsessive-compulsive disorder based on (Y-BOCS) YALE-BROWN OBSESSIVE COMPULSIVE SCALE. Timepoint: Before intervention and 1 month, 2 months and 3 months after intervention. Method of measurement: Yale–Brown Obsessive Compulsive Scale.
- Secondary Outcome Measures
Name Time Method Comparison of quantitative electroencephalographic (QEEG) changes in different groups. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Quantitative Electroencephalogram.